Christine Günther

Treatment of advanced gastrointestinal tumors with genetically modified autologous mesenchymal stromal cells (TREAT-ME1): study protocol of a phase I/II clinical trial

Jobst C. von Einem, Michael Thomas, Marlies Michl et al. · BMC Cancer · 2015 · 115 citations · Full text

IL7-IL12 Engineered Mesenchymal Stem Cells (MSCs) Improve A CAR T Cell Attack Against Colorectal Cancer Cells

Andreas Hombach, Ulf Geumann, Christine Günther et al. · Cells · 2020 · 95 citations · Full text

Cell Therapy, Immunology, Immune Regulation +19

Ligand-Modified Human Serum Albumin Nanoparticles for Enhanced Gene Delivery

J.L. Look, Nadine Wilhelm, Hagen von Briesen et al. · Molecular Pharmaceutics · 2015 · 67 citations

Nanoparticles, Nanomedicine, Engineering +12

High levels of BAX, low levels of MRP-1, and high platelets are independent predictors of response to imatinib in myeloid blast crisis of CML

Thoralf Lange, Christine Günther, Thomas Köhler et al. · Blood · 2003 · 45 citations · Full text

Treatment of advanced gastrointestinal cancer with genetically modified autologous mesenchymal stem cells - TREAT-ME-1 - a phase I, first in human, first in class trial

Jobst C. von Einem, Sylvia Peter, Christine Günther et al. · Oncotarget · 2017 · 45 citations · Full text